tions (10,024,075) (9,876,760) (33,225,627) (29,652,777)
Interest income 126,655 221,333 481,855 747,921
Interest expense (159,359) (241,735) (528,924) (292,018)
Other income - - 75,000 976,815
Net loss $(10,056,779) $(9,897,162) $(33,197,696) $(28,220,059)
Basic and diluted
net loss per share $(0.22) $(0.33) $(0.78) $(0.93)
Shares used in
calculation of basic
and diluted net
loss per share 46,650,833 30,302,628 42,831,867 30,209,948
MIDDLEBROOK PHARMACEUTICALS, INC.
CONDENSED BALANCE SHEETS
(Unaudited)
September 30, December 31,
2007 2006
ASSETS
Current assets:
Cash and cash equivalents $4,987,690 $14,856,738
Marketable securities 929,812 522,723
Accounts receivable, net 1,331,764 303,514
Inventories, net 1,088,913 2,077,390
Prepaid expenses and other
current assets 1,199,515 1,682,685
Total current assets 9,537,694 19,443,050
Property and equipment, net 11,533,248 11,764,627
Restricted cash 872,180 872,180
Deposits and other assets 348,006 1,548,585
Intangible assets, net 7,509,070 8,377,327
Total assets $29,800,198 $42,005,769
LIABILITIES AND STOCKHOLDERS' EQUITY
'/>"/>SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related medicine news :1.
MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management2.
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference3.
Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet4.
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma5.
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences6.
Vista Partners Updates Coverage on Tapestry Pharmaceuticals7.
Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference8.
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.9.
Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes10.
Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs11.
Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study